Self-Study 2026: Updates on Anti-HER2 Therapies in Non-Small Cell Lung Cancer

Type: Individual•Format: On-demand

Human epidermal growth factor receptor 2 (HER2/ERBB2) is a tyrosine kinase receptor and oncogene which drives cell proliferation and survival. Alterations in HER2 can be seen in various malignancies including breast cancer, colon cancer, and lung cancer. Specifically, in non-small cell lung cancer (NSCLC) patients, the HER2 signaling pathway may be activated via gene mutations, gene amplification or protein overexpression. Treatment options for HER2-altered NSCLC may include tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADC). Research is ongoing, with clinical trials exploring new combinations and agents for HER2-altered NSCLC.

Updates on Anti-HER2 Therapies in Non-Small Cell Lung Cancer

Author: Alexis H. Koon, PharmD, BCOP - Clinical Pharmacy Specialist, Sarcoma/Thoracic Oncology

Learning Objectives

  1. Review the prevalence and detection methodologies of HER2 gene expression in NSCLC
  2. Identify the place in therapy for zongertinib in HER2+ NSCLC patients
  3. Evaluate the toxicities and clinical outcomes of trastuzumab deruxtecan in HER+ NSCLC patients
  4. Create a treatment plan for a patient with HER2+ NSCLC advanced or metastatic disease with progression after first-line therapy

Get it here

Application Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.